NTRP shows severe operational deterioration with gross profit collapsing 95% and revenue declining 39%, despite significant equity dilution that increased stockholders' equity by 136%.
The company appears to have raised substantial capital (evidenced by the dramatic increase in outstanding shares from 1.4M to 7.7M and stockholders' equity growth), but this dilution coincided with catastrophic operational performance. The near-complete erosion of gross profit margin suggests fundamental business model challenges that fresh capital alone may not resolve.
NTRP experienced a tale of two extremes - balance sheet strength improved dramatically with cash increasing 228% and total assets nearly doubling, clearly indicating a significant capital raise through massive share dilution (450% increase in share count). However, operational performance collapsed with gross profit falling 95% and revenue declining 39%, while net losses widened to $10.1M. The juxtaposition of abundant fresh capital against deteriorating core business metrics suggests the company bought time but has not yet solved its fundamental profitability challenges.
Cash position surged 228.1% — strong cash generation or capital raise providing significant financial cushion.
Capital expenditure jumped 216% — major investment cycle underway; assess returns on deployment.
Equity base grew 135.5% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 95.3% — expansion through organic growth, acquisitions, or capital deployment.
Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.
Current assets grew 45.1% — improving short-term liquidity or inventory/receivables build.
Revenue declined 39.4% — significant demand weakness or market share loss warrants investigation.
Net income declined 38% — review whether driven by operations, interest costs, or non-recurring items.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Inventory surged 33.9% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →